GEN presents data compiled by Morningstar's Morningstar Direct asset management platform for StockWatch of the top five ...

Mesoblast Ltd (MESO) stock saw a modest uptick, ending the day at $16.76 which represents a slight increase of $4.51 or 36.82% from the prior close of $12.25. The stock opened at $18.68 and touched a ...

Mesoblast Limited (AU:MSB) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

The local bourse hit a three-month low on Friday as CBA led banks down, Mesoblast gave back some of its gains and the ASX had ...

Investors are sending the Mesoblast share price tumbling on Friday. But why? The post Why the Mesoblast share price is diving ...

Regenerative medicine company Mesoblast Ltd. received an early Christmas present from the FDA for approval of its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil ...

Mesoblast’s stock surged on Thursday after the company won FDA approval for its twice-rejected graft-versus-host disease ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

Ryoncil is part of a development programme for inflammatory diseases such as SR-aGvHD in adults, and biologic-res ...

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...